Jubilant Life Sciences' net profit rises by 65 per cent

The flagship company of Jubilant Group, Jubilant Life Sciences on May 24 has declared its Q4FY16 results, wherein the company recorded a net profit of Rs 70.68 crores. Net profit of Jubilant Life Sciences has increased by 65 per cent as compared to Q4FY15. EBITDA for the period stands at Rs 320.24 crores, which has increased by 29 per cent over the previous quarter. Total income from operations stands at Rs 1501.27 crores for the quarter, as against Rs 1536.54 crores for the corresponding period of the previous fiscal. Total income of the company has decreased by 2 per cent. 

On a YoY basis, net profit for the period stands at Rs 439.49 crores, whereas for the previous fiscal, the company had reported a net loss of Rs 57.76 crores. EBITDA stands at Rs 1277.78 crores, while previously EBITDA was reported at Rs 689.53 crores. Consolidated total income for the period stands at Rs 5802.32 crores.

On a CAGR basis, the company’s EBITDA for the period of 3 years has grown by 13 per cent. Company has posted a double digit growth largely due to good volume sales of sterile products in the pharma- segment, wherein the company has benefited, as the product operates in a niche market segment.

Jubilant Life Sciences Limited, is an integrated global pharmaceutical and life sciences company engaged in manufacturing and supply of APIs (Active Pharmaceutical Ingredients), solid dosage formulations, radiopharmaceuticals, allergy therapy products, advance intermediates, fine ingredients, crop science ingredients, life science chemicals and nutritional products. It also provides services in contract manufacturing of sterile injectable and drug discovery solutions.

The shares of the company on Wednesday have opened negative and are trading at Rs 353.60, marginally down by 0.11 per cent.